Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a market which is becoming increasingly crowded. Vera Therapeutics reported ...
In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback